We are excited to showcase a robust scientific presence at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal, with more than 45 abstracts highlighting our commitment to advancing the science in cardiovascular and metabolic diseases (CVMD).
Recent scientific developments point to the need to move beyond lowering blood sugar levels towards a treatment paradigm that supports people with diabetes earlier and in a holistic manner. From pivotal cardiovascular outcomes trial data in type-2 diabetes, exploring outcomes in type-1 diabetes with novel therapies, to evidence grounded in real-world clinical practice across AstraZeneca’s portfolio, our data at EASD represents our commitment to investing in pioneering, distinctive science at the forefront of clinical debate.
Follow us on Twitter @AstraZeneca, and join the conversation #EASD2017.
Supporting the next generation of leading clinical diabetologists in Europe
In addition to our scientific presence, during EASD the European Foundation for the Study of Diabetes (EFSD) is hosting its inaugural meeting on 12 September at 13:30 GMT to announce the first 5 selected mentees of their Future Leaders Mentorship Programme for Clinical Diabetologists, of which AstraZeneca is the sole supporter. The aim of the Mentorship Programme is to identify and promote the advancement of the next generation of leading clinical diabetologists in Europe.
Chosen applicants will have the unique opportunity to take part in a broad range of educational and training opportunities centered around a clinical research project, with leading European clinical diabetologists serving as personal mentors. Through its various activities, the Mentorship Programme will help mentees develop into leaders by refining their skills in the three cardinal areas of clinical diabetes, research and communication, thereby keeping them in the field of diabetes and facilitating their appointment to senior academic positions at major European institutions.
AstraZeneca’s EASD Presence in Review
AstraZeneca invests in science focused on the overlap between CV, renal and metabolic diseases. Are you ready to see how at EASD 2017 meeting?
Diabetes rates are projected to rise considerably through 2040. AstraZeneca is investing in innovative therapies to combat the burden, together.
Hear Elisabeth Bjork, VP, Global Medicines Development Unit Head, CVMD, highlight AstraZeneca’s unique approach to supporting people at the intersection of type-2 diabetes and CVMD conditions.
Ludovic Helfgott, VP, CVMD, speaks to AstraZeneca’s pursuit of distinctive science at the forefront of clinical debate.
Veeva ID: Z4-6493
Date of next review: August 2018